Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EPHX2 | P34913 | 13/20 | 0.49 |
| ▸ | HDAC1 | Q13547 | 4/20 | 0.46 |
| ▸ | HDAC8 | Q9BY41 | 4/20 | 0.46 |
| ▸ | HDAC6 | Q9UBN7 | 4/20 | 0.46 |
| ▸ | HDAC3 | O15379 | 3/20 | 0.46 |
| ▸ | GRIN2D | O15399 | 1/20 | 0.43 |
| ▸ | GRIN3B | O60391 | 1/20 | 0.43 |
| ▸ | GRIN1 | Q05586 | 1/20 | 0.43 |
| ▸ | GRIN2A | Q12879 | 1/20 | 0.43 |
| ▸ | GRIN2B | Q13224 | 1/20 | 0.43 |
| ▸ | GRIN2C | Q14957 | 1/20 | 0.43 |
| ▸ | GRIN3A | Q8TCU5 | 1/20 | 0.43 |
| ▸ | TSHR | P16473 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL733617 | 0.87 | EPHX2 (0.62) | EPHX2HDAC1HDAC8HDAC6HDAC3 | |
| SCHEMBL12858009 | 0.87 | EPHX2 (0.57) | EPHX2HDAC1HDAC8HDAC6HDAC3 | |
| SCHEMBL5608363 | 0.79 | EPHX2 (0.50) | EPHX2HDAC1HDAC8HDAC6HDAC3 | |
| SCHEMBL4879234 | 0.77 | EPHX2 (0.48) | EPHX2HDAC1HDAC8HDAC6HDAC3 | |
| SCHEMBL4887810 | 0.76 | GAA (0.40) | EPHX2TSHR | |
| SCHEMBL21461244 | 0.76 | EPHX2 (0.62) | EPHX2HDAC1HDAC8HDAC6HDAC3 | |
| SCHEMBL21461245 | 0.76 | EPHX2 (0.62) | EPHX2HDAC1HDAC8HDAC6HDAC3 | |
| SCHEMBL21461246 | 0.76 | EPHX2 (0.62) | EPHX2HDAC1HDAC8HDAC6HDAC3 | |
| SCHEMBL15228444 | 0.76 | EPHX2 (0.62) | EPHX2HDAC1HDAC8HDAC6HDAC3 | |
| Acetamide SCHEMBL4785229 | 0.76 | GRIN1 (0.45) | EPHX2HDAC1HDAC8HDAC6HDAC3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20080275112-A1 | Invention Concerning Aminoadamantane Compounds | SCHREINER PETER R | 2008-11-06 | — | — | US | disclosed |
| EP-1789380-A1 | AMINO ADAMANTANE DERIVATIVES, METHODS FOR THE PRODUCTION AND USE THEREOF | Justus-Liebig-Universität Giessen (DE) | 2007-05-30 | — | — | EP | disclosed |
| WO-2006010362-A1 | AMINO ADAMANTANE DERIVATIVES, METHODS FOR THE PRODUCTION AND USE THEREOF | JUSTUS-LIEBIG-UNIVERSITÄT GIESSEN (DE) | 2006-02-02 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080275112-A1 | Invention Concerning Aminoadamantane Compounds | GABRA5, GABRA1, GABRA4 | EPHX2 2455/4885HDAC1 3733/4885HDAC8 3720/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.